Cargando…
Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or tr...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072651/ https://www.ncbi.nlm.nih.gov/pubmed/33920503 http://dx.doi.org/10.3390/pharmaceutics13040570 |
_version_ | 1783683956144603136 |
---|---|
author | Frickenstein, Alex N. Hagood, Jordan M. Britten, Collin N. Abbott, Brandon S. McNally, Molly W. Vopat, Catherine A. Patterson, Eian G. MacCuaig, William M. Jain, Ajay Walters, Keisha B. McNally, Lacey R. |
author_facet | Frickenstein, Alex N. Hagood, Jordan M. Britten, Collin N. Abbott, Brandon S. McNally, Molly W. Vopat, Catherine A. Patterson, Eian G. MacCuaig, William M. Jain, Ajay Walters, Keisha B. McNally, Lacey R. |
author_sort | Frickenstein, Alex N. |
collection | PubMed |
description | Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations. |
format | Online Article Text |
id | pubmed-8072651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80726512021-04-27 Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect Frickenstein, Alex N. Hagood, Jordan M. Britten, Collin N. Abbott, Brandon S. McNally, Molly W. Vopat, Catherine A. Patterson, Eian G. MacCuaig, William M. Jain, Ajay Walters, Keisha B. McNally, Lacey R. Pharmaceutics Review Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations. MDPI 2021-04-17 /pmc/articles/PMC8072651/ /pubmed/33920503 http://dx.doi.org/10.3390/pharmaceutics13040570 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Frickenstein, Alex N. Hagood, Jordan M. Britten, Collin N. Abbott, Brandon S. McNally, Molly W. Vopat, Catherine A. Patterson, Eian G. MacCuaig, William M. Jain, Ajay Walters, Keisha B. McNally, Lacey R. Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect |
title | Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect |
title_full | Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect |
title_fullStr | Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect |
title_full_unstemmed | Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect |
title_short | Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect |
title_sort | mesoporous silica nanoparticles: properties and strategies for enhancing clinical effect |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072651/ https://www.ncbi.nlm.nih.gov/pubmed/33920503 http://dx.doi.org/10.3390/pharmaceutics13040570 |
work_keys_str_mv | AT frickensteinalexn mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT hagoodjordanm mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT brittencollinn mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT abbottbrandons mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT mcnallymollyw mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT vopatcatherinea mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT pattersoneiang mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT maccuaigwilliamm mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT jainajay mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT walterskeishab mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect AT mcnallylaceyr mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect |